208 related articles for article (PubMed ID: 36722252)
1. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
[TBL] [Abstract][Full Text] [Related]
2. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.
Villaschi A; Ferrante G; Cannata F; Pini D; Pagnesi M; Corrada E; Reimers B; Mehran R; Federici M; Savarese G; Metra M; Condorelli G; Stefanini GG; Chiarito M
Clin Res Cardiol; 2024 Jun; 113(6):898-909. PubMed ID: 38252145
[TBL] [Abstract][Full Text] [Related]
3. Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
Ferreira JP; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
Eur J Heart Fail; 2022 Oct; 24(10):1792-1801. PubMed ID: 36053803
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
5. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
7. Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kunutsor SK; Khunti K; Seidu S
J R Soc Med; 2023 Sep; ():1410768231198442. PubMed ID: 37734450
[TBL] [Abstract][Full Text] [Related]
8. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Marso SP; Baeres FMM; Bain SC; Goldman B; Husain M; Nauck MA; Poulter NR; Pratley RE; Thomsen AB; Buse JB;
J Am Coll Cardiol; 2020 Mar; 75(10):1128-1141. PubMed ID: 32164886
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
10. Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.
Gu X; Jiang S; Yang Y; Li W
Diabetol Metab Syndr; 2024 Jan; 16(1):14. PubMed ID: 38212831
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Zhao H; Liu Y; Liu M; Xu Y; Ling Q; Lin W; Zhang J; Yan Z; Ma J; Li W; Zhao Y; Yu P; Liu X; Wang J
Drugs; 2023 Sep; 83(14):1293-1307. PubMed ID: 37639180
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).
Ghosal S; Datta D; Sinha B
Sci Rep; 2021 Nov; 11(1):22063. PubMed ID: 34764398
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
Michos ED; Bakris GL; Rodbard HW; Tuttle KR
Am J Prev Cardiol; 2023 Jun; 14():100502. PubMed ID: 37313358
[TBL] [Abstract][Full Text] [Related]
14. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
[TBL] [Abstract][Full Text] [Related]
16. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.
Kelly M; Lewis J; Rao H; Carter J; Portillo I; Beuttler R
Pharmacotherapy; 2022 Dec; 42(12):921-928. PubMed ID: 36271706
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.
Dotan I; Rudman Y; Turjeman A; Akirov A; Steinmetz T; Calvarysky B; Diker Cohen T
Transplantation; 2024 Jul; 108(7):e121-e128. PubMed ID: 38361246
[TBL] [Abstract][Full Text] [Related]
18. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
19. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.
Cromer SJ; Lauffenburger JC; Levin R; Patorno E
Diabetes Care; 2023 Jan; 46(1):65-74. PubMed ID: 36383481
[TBL] [Abstract][Full Text] [Related]
20. Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.
Zhao LM; Huang JN; Qiu M; Ding LL; Zhan ZL; Ning J
Medicine (Baltimore); 2021 Oct; 100(39):e27362. PubMed ID: 34596148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]